U.S. Senator Chris Murphy (D-Conn.) recently recognized Aspira Women’s Health, a bio-analytical company based in Shelton, Connecticut, as “Innovator of the Month.” This honor highlights Aspira’s leadership in advancing diagnostic solutions for women’s health, including the development of AI-powered blood tests for ovarian cancer detection.
Aspira’s flagship products, OvaWatch and Ova1Plus, are transforming ovarian cancer risk assessment by providing more accurate and non-invasive diagnostic tools, thereby elevating the standard of care for women with ovarian masses. In a major stride, the company was recently awarded $10 million in federal funding to develop a groundbreaking non-invasive blood test for endometriosis—a condition currently diagnosed primarily through invasive surgery.
A Legacy of Underinvestment in Women’s Health
“For too long, women’s health has been underfunded and overlooked, leaving women and girls without the care they need and deserve,” said Senator Murphy. “Aspira’s groundbreaking work in biomedical research is not only positioning Connecticut as a leader in women’s healthcare innovation but also improving lives through earlier detection, better diagnoses, and more personalized care.”
Empowering Women with Non-Invasive Diagnostics
Aspira’s CEO, Nicole Sandford, expressed gratitude for the recognition and reiterated the company’s commitment to advancing healthcare solutions for women.
“Being named Innovator of the Month underscores the importance of our mission to shift the paradigm in diagnosing gynecologic conditions,” said Sandford. “Endometriosis, a chronic condition affecting up to six million women in the U.S., profoundly impacts quality of life. Patients often endure years of suffering before receiving a diagnosis, largely due to the lack of non-invasive diagnostic options. At Aspira, we leverage advanced data analytics and AI algorithms to deliver non-invasive solutions that empower women to make informed decisions about their health.”
Aspira has already made a significant impact in ovarian cancer diagnostics. Its blood tests have been utilized by healthcare providers over 200,000 times, enabling earlier and more precise ovarian cancer risk assessments. Sandford believes this expertise uniquely positions the company to revolutionize endometriosis diagnosis.
Innovations in Gynecologic Diagnostics
Aspira Women’s Health specializes in the discovery, development, and commercialization of AI-driven diagnostic tools for gynecologic diseases. Its flagship diagnostic portfolio, OvaSuiteSM, includes OvaWatch® and Ova1Plus®. These tests represent a comprehensive approach to ovarian cancer risk assessment for the more than 1.2 million women in the U.S. diagnosed with adnexal masses annually.
- OvaWatch® offers a negative predictive value of 99%, making it a critical tool for assessing cancer risk in women whose initial evaluations suggest their ovarian mass is indeterminate or benign. This can help avoid premature or unnecessary surgeries.
- Ova1Plus® combines two FDA-cleared tests, Ova1® and Overa®, into a reflex testing process that assesses malignancy risk for women undergoing surgery for an adnexal mass.
The Path Forward
Aspira’s efforts are not only addressing critical gaps in women’s healthcare but also aligning with broader trends in AI-driven medicine. Their work exemplifies how artificial intelligence can be harnessed to create targeted, data-driven healthcare solutions that improve outcomes and reduce reliance on invasive procedures.
As Aspira develops its endometriosis blood test, the potential impact extends far beyond diagnostics. Early detection and better disease management could significantly improve patient quality of life, reduce healthcare costs, and provide a model for addressing other underdiagnosed conditions in women’s health.
Are you interested in how AI is changing healthcare? Subscribe to our newsletter, “PulsePoint,” for updates, insights, and trends on AI innovations in healthcare.
